Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


EU Guide Aims To Help Manufacturers Avoid Setting Off 'False Alarms' Under FMD

Group Concerned About Low Rate Of EMVS Adoption

Executive Summary

To reduce false alarms of counterfeits, EU tells drugmakers no lowercase, hyphens, question marks or certain letters in serial and batch numbers.

You may also be interested in...

Six-Month Delay For Russia’s Track And Trace System

Russia’s new drug traceability system won’t now be implemented until July, but companies that are ready and able are being encouraged to put the system through its paces in order to flush out any glitches.

EU 'Aide-Memoire' Outlines Systems That Should Be In Place For Compliance With FMD

An EU guide sheds some light on what inspectors will be looking for in audits to ensure that manufacturers have the safety features required to comply with the EU's Falsified Medicines Directive.

Europe’s Medicines Verification System Prepares To Go Live

Europe’s ambitious new system for verifying the authenticity of prescription medicines circulating on the market is about to come into operation.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts